TY - JOUR
T1 - Cancer- and chemotherapy-induced anemia
T2 - Clinical practice guidelines in oncology
AU - Rodgers, George M.
AU - Becker, Pamela Sue
AU - Blinder, Morey
AU - Cella, David
AU - Chanan-Khan, Asher
AU - Cleeland, Charles
AU - Coccia, Peter F.
AU - Djulbegovic, Benjamin
AU - Gilreath, Jeffrey A.
AU - Kraut, Eric H.
AU - Matulonis, Ursula A.
AU - Millenson, Michael M.
AU - Reinke, Denise
AU - Rosenthal, Joseph
AU - Schwartz, Rowena N.
AU - Soff, Gerald
AU - Stein, Richard S.
AU - Vlahovic, Gordana
AU - Weir, Alva B.
PY - 2012/5/1
Y1 - 2012/5/1
N2 - Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.
AB - Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.
UR - http://www.scopus.com/inward/record.url?scp=84861818190&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2012.0064
DO - 10.6004/jnccn.2012.0064
M3 - Review article
C2 - 22570293
AN - SCOPUS:84861818190
SN - 1540-1405
VL - 10
SP - 628
EP - 653
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5
ER -